Equities research analysts expect that aTyr Pharma, Inc. (NASDAQ:LIFE) will report ($0.35) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for aTyr Pharma’s earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.38). aTyr Pharma reported earnings of ($0.56) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 37.5%. The firm is expected to announce its next earnings report on Thursday, May 10th.

On average, analysts expect that aTyr Pharma will report full year earnings of ($1.40) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.03). For the next year, analysts anticipate that the firm will post earnings of ($1.62) per share, with EPS estimates ranging from ($2.25) to ($1.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for aTyr Pharma.

aTyr Pharma (NASDAQ:LIFE) last posted its earnings results on Monday, March 19th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04.

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Friday, March 9th. JPMorgan Chase cut shares of aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $4.67.

Hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG purchased a new position in aTyr Pharma in the 4th quarter worth approximately $199,000. Dimensional Fund Advisors LP grew its stake in aTyr Pharma by 44.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after buying an additional 25,676 shares in the last quarter. Renaissance Technologies LLC grew its stake in aTyr Pharma by 143.2% in the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after buying an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. grew its stake in aTyr Pharma by 100.0% in the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after buying an additional 250,000 shares in the last quarter. 58.81% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma stock opened at $2.40 on Thursday. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.23. aTyr Pharma has a 1-year low of $2.30 and a 1-year high of $6.50.

TRADEMARK VIOLATION WARNING: “aTyr Pharma, Inc. (LIFE) Expected to Announce Earnings of -$0.35 Per Share” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/04/22/atyr-pharma-inc-life-expected-to-announce-earnings-of-0-35-per-share.html.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.